Rani Therapeutics Holdings, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2021
Rani estimates that net loss will be between $53.0 million and $55.0 million for the full-year 2021, compared to $16.7 million for full-year 2020. The net loss includes estimated equity-based compensation expense of approximately $3.2 million for the fourth quarter of 2021 and approximately $22.6 million for the full-year 2021. There was no equity-based compensation expense for the fourth quarter of 2020 nor full year-year 2020.